PAI-1

PAI-1製品

All (7)
PAI-1阻害剤 (7)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S7922	Tiplaxtinin (PAI-039)	Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM.	Nat Commun, 2023, 14(1):3505 Nat Commun, 2023, 14(1):3505 Cell Death Dis, 2023, 14(9):614
S3785	Notoginsenoside R1	Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.	Food Sci Nutr, 2023, 11(12):7791-7802 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S9194	Toddalolactone	Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.
S3242	Loureirin B	Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the K_ATP current, influx of Ca²⁺ to the intracellular.
E1603	ACT001(DMAMCL)	ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway.
S6776	TM5275 Sodium	TM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM.
S6778	TM5441	TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.
S7922	Tiplaxtinin (PAI-039)	Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM.	Nat Commun, 2023, 14(1):3505 Nat Commun, 2023, 14(1):3505 Cell Death Dis, 2023, 14(9):614
S3785	Notoginsenoside R1	Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.	Food Sci Nutr, 2023, 11(12):7791-7802 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S9194	Toddalolactone	Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.
S3242	Loureirin B	Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the K_ATP current, influx of Ca²⁺ to the intracellular.
E1603	ACT001(DMAMCL)	ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway.
S6776	TM5275 Sodium	TM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM.
S6778	TM5441	TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.

PAI-1阻害剤の選択性比較